Your browser doesn't support javascript.
loading
Treatment options in hypoparathyroidism.
Sakane, Eliane Naomi; Vieira, Maria Carolina Camargo; Vieira, Gabriela Mazzarolo Marcondes; Maeda, Sergio Setsuo.
Afiliação
  • Sakane EN; Departamento de Medicina, Disciplina de Endocrinologia, Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brasil.
  • Vieira MCC; Departamento de Medicina, Disciplina de Endocrinologia, Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brasil.
  • Vieira GMM; Departamento de Medicina, Disciplina de Endocrinologia, Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brasil.
  • Maeda SS; Departamento de Medicina, Disciplina de Endocrinologia, Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brasil, ssetsuo@terra.com.br.
Arch Endocrinol Metab ; 66(5): 651-657, 2022 Nov 11.
Article em En | MEDLINE | ID: mdl-36382754
Hypoparathyroidism remains the single endocrine deficiency disease that is not habitually treated with the missing hormone. In this article, we aim to provide a review of the conventional approach and the novel therapies as well as an overview of the perspectives on the treatment of this rare condition. We conducted a literature review on the conventional therapy using vitamin D analogs and calcium salts, indications for thiazide diuretics and phosphorus binders, PTH analogs history and usage, and the drugs that are currently being tested in clinical trials. Conventional treatment involves calcium salts and vitamin D analogs. Thiazide diuretics can be used to reduce hypercalciuria in some cases. A low-phosphate diet is recommended, and phosphate binders are rarely needed. During pregnancy, a careful approach is necessary. The use of PTH analogs is a new approach despite the limitation of high cost. Studies have included modified PTH molecules, calcilytics, microencapsulation of human parathyroid cells, and allotransplantation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hormônio Paratireóideo / Hipoparatireoidismo Limite: Humans Idioma: En Revista: Arch Endocrinol Metab Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hormônio Paratireóideo / Hipoparatireoidismo Limite: Humans Idioma: En Revista: Arch Endocrinol Metab Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Brasil País de publicação: Brasil